Published in Epilepsia on April 19, 2011
Single-neuron correlates of atypical face processing in autism. Neuron (2013) 0.96
Common neurological co-morbidities in autism spectrum disorders. Curr Opin Pediatr (2011) 0.92
Ketogenic diet improves core symptoms of autism in BTBR mice. PLoS One (2013) 0.90
Studying autism in rodent models: reconciling endophenotypes with comorbidities. Front Hum Neurosci (2013) 0.90
A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Front Public Health (2013) 0.88
Metabolic mapping of deep brain structures and associations with symptomatology in autism spectrum disorders. Res Autism Spectr Disord (2014) 0.84
Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes. Clin Med Insights Pediatr (2016) 0.82
Adenosine and autism: a spectrum of opportunities. Neuropharmacology (2012) 0.79
Ketogenic diets improve behaviors associated with autism spectrum disorder in a sex-specific manner in the EL mouse. Physiol Behav (2016) 0.77
Beta-lactam antibiotics as a possible novel therapy for managing epilepsy and autism, a case report and review of literature. Iran J Child Neurol (2015) 0.76
The Current Status of the Ketogenic Diet in Psychiatry. Front Psychiatry (2017) 0.75
Neuropathological Mechanisms of Seizures in Autism Spectrum Disorder. Front Neurosci (2016) 0.75
Prevalence of non-febrile seizures in children with idiopathic autism spectrum disorder and their unaffected siblings: a retrospective cohort study. BMC Neurol (2016) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 9.32
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med (2004) 8.98
De novo mutations in epileptic encephalopathies. Nature (2013) 7.42
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med (2003) 6.73
A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 6.20
Cumulative effects associated with recurrent concussion in collegiate football players: the NCAA Concussion Study. JAMA (2003) 6.08
Acute effects and recovery time following concussion in collegiate football players: the NCAA Concussion Study. JAMA (2003) 5.68
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway. Nat Med (2010) 4.24
The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol (2010) 4.06
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Oral tolerance. Immunol Rev (2005) 3.48
Anterior temporal lobectomy with amygdalohippocampectomy for mesial temporal sclerosis: predictors of long-term seizure control. J Neurosurg (2013) 3.29
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol (2010) 3.00
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med (2006) 2.93
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest (2012) 2.67
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol (2009) 2.56
The human K-complex represents an isolated cortical down-state. Science (2009) 2.54
T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc Natl Acad Sci U S A (2010) 2.41
The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A (2009) 2.38
Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary. Nat Rev Drug Discov (2008) 2.30
Cannabinoids in the Treatment of Epilepsy. N Engl J Med (2015) 2.27
An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2010) 2.21
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol (2004) 2.11
Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A (2010) 2.10
IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol (2009) 2.00
Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol (2011) 1.93
Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation (2002) 1.80
PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol (2004) 1.78
Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci (2003) 1.77
CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol (2003) 1.75
IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol (2006) 1.72
Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging (2009) 1.70
What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol (2007) 1.64
Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol (2006) 1.63
Heterogeneous neuronal firing patterns during interictal epileptiform discharges in the human cortex. Brain (2010) 1.62
A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev (2006) 1.62
Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest (2008) 1.61
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
Health-related quality of life over time since resective epilepsy surgery. Ann Neurol (2007) 1.59
TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol (2006) 1.58
Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging (2002) 1.57
Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis. Ann Neurol (2010) 1.56
Race/ethnicity, sex, and socioeconomic status as predictors of outcome after surgery for temporal lobe epilepsy. Arch Neurol (2006) 1.55
Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci (2005) 1.54
Immunotherapeutic approaches to Alzheimer's disease. Science (2003) 1.52
Epilepsy surgery for children with tuberous sclerosis complex. J Child Neurol (2004) 1.52
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler (2013) 1.51
Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol (2008) 1.48
Selective emotional detachment from family after right temporal lobectomy. Epilepsy Behav (2003) 1.47
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology (2013) 1.46
Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One (2013) 1.45
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest (2005) 1.45
Impaired consciousness in temporal lobe seizures: role of cortical slow activity. Brain (2010) 1.44
Slow cortical dynamics and the accumulation of information over long timescales. Neuron (2012) 1.42
Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol (2010) 1.42
The excitable cerebral cortex Fritsch G, Hitzig E. Uber die elektrische Erregbarkeit des Grosshirns. Arch Anat Physiol Wissen 1870;37:300-32. Epilepsy Behav (2009) 1.42
Neuroinflammation and psychiatric illness. J Neuroinflammation (2013) 1.42
Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline. Neuropsychology (2008) 1.41
Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J Immunol (2003) 1.40
Mesenteric lymph nodes are critical for the induction of high-dose oral tolerance in the absence of Peyer's patches. Eur J Immunol (2002) 1.40
Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J Immunol (2007) 1.39
Do tubers contain function? Resection of epileptogenic foci in perirolandic cortex in children with tuberous sclerosis complex. Epilepsia (2010) 1.39
Epilepsy surgery in young children with tuberous sclerosis: results of a novel approach. Pediatrics (2006) 1.37
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain (2008) 1.34
Gut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology (2011) 1.34
Systems biology approaches for the study of multiple sclerosis. J Cell Mol Med (2008) 1.33
The epilepsy phenome/genome project. Clin Trials (2013) 1.32
MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS. Glia (2012) 1.32
Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset. J Immunol (2010) 1.31
Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2012) 1.31
Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.30
Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes (2007) 1.29
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology (2003) 1.29
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med (2012) 1.29
Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol (2004) 1.28
Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci U S A (2010) 1.26
Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol (2008) 1.26
Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol (2006) 1.26
The importance of cell-mediated immunity in the course and severity of autoimmune anti-glomerular basement membrane disease in mice. FASEB J (2003) 1.25
Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging (2011) 1.24
The treatment of nonepileptic seizures: historical perspectives and future directions. Epilepsia (2004) 1.24
Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response. Epilepsy Behav (2010) 1.23